Here’s what I think is the global healthcare business model that slowed DCVax but still allows L to ultimately step forward. (FDA/SEC are captive to special interests.)
BP products will be disrupted by DCVax, cancer surgery economy would be disrupted by DCVax-Direct, NVCR will be decimated by L and/or direct, high cost clean rooms and excessive employee count will be unnecessary with Eden and its offspring.
L is like a godsend to make the transition to better patient treatment more palatable to all the above self-interested groups. It combines with current lucrative BP products, it still requires surgery or at least large biopsy material, it still requires clean room production and associated workers for now.
L is essentially a decompression chamber so that all the above interests don’t get the Benz as medical care surfaces toward a better and more humane approach. Direct will eventually move forward, imho, but the above forces trying to hold it off will need time to come to terms with their respective sugar daddies’ mortality.
News 
Market Data 
Discover 
